In Cohort 3, 14 subjects who received CPL-01 showed a mean AUC through 72 h of wWOCF adjusted NRS-A (the primary endpoint) that showed a trend towards significance as compared to the 13 subjects who received placebo (p = 0.08) and numerically better than the 40 subjects who received Naropin.
Results for all groups are presented in Table 1 . Subjects who received the highest dose of CPL-01 in Cohort 3 had a mean (SD) AUC 0-72 of 286.8 (113.70), which was the lowest value for any treatment group in all cohorts, showing a trend towards significance as compared to the pooled placebo group (mean AUC 0-72 of 369.2, p = 0.08) and numerically lower than the mean (SD) AUC 0-72 of 322.5 (176.63) for the pooled NAROPIN group.